

Comparison of the incidence of epistaxis following nasotracheal intubation when using either the fiberoptic laryngoscope technique or the Macintosh laryngoscope technique

Submission date 28/09/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 28/09/2007	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 12/10/2017	Condition category Surgery	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr JE Smith

Contact details
Anaesthetics
Selly Oak Hospital
Birmingham
United Kingdom
B29 6JD

Additional identifiers

Protocol serial number
N0265170229

Study information

Scientific Title

Comparison of the incidence of epistaxis following nasotracheal intubation when using either the fiberoptic laryngoscope technique or the Macintosh laryngoscope technique

Study objectives

1. When performing nasotracheal intubation (passage of breathing tube through the nose, pharynx and larynx into the windpipe) under general anaesthesia, does fiberoptic intubation reduce the incidence of epistaxis (nosebleed) in comparison with traditional intubation using the Macintosh laryngoscope?
2. Secondary research questions/objectives include:
 - 2.1 Does it reduce the severity of epistaxis?
 - 2.2 Does it reduce the number of attempts necessary to pass the tube through the nose?
 - 2.3 Does it reduce the resistance encountered when passing the tube through the nose?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Surgery: Intubation

Interventions

Patients will be asked the following questions: (1) Do you have any difficulty breathing through your nose? (2) Can you usually breathe clearly through both nostrils? (3) Can you usually breathe equally through both nostrils or is one nostril clearer than the other? Only asymptomatic patients who report being able to breathe clearly and equally through both nostrils will be invited to participate in the study.

Xylometazoline (a vasoconstrictor) will be applied to the nasal mucosa approximately thirty minutes and then approximately 5 minutes before the induction of anaesthesia. Anaesthesia will be established with glycopyrrolate, fentanyl, propofol and atracurium and the patients lungs will be ventilated with oxygen and isoflurane until neuromuscular blockade is complete.

Patients will then be randomised into two groups, the Fiberoptic Laryngoscope group or the Macintosh Laryngoscope group, by opening an opaque, sealed envelope. All fiberoptic and Macintosh intubations will be performed by experienced anaesthetists (JES or JLT). In the Fiberoptic group, each nostril will be examined systematically with a videoendoscope (an endoscope attached to a closed circuit television system), and a videotape recording of the procedure will be made following General Medical Council guidelines. Following anterior rhinoscopy (inspection of the front of the nasal cavity), the fibrescope will be passed both

underneath and alongside the inferior turbinate in each nostril and any resistance to the passage of the instrument along these pathways will be noted. The presence of any intranasal abnormalities will be documented. The most patent nostril (if any) will be selected for the nasal intubation. If the nostrils are considered to be equally patent, a random selection will be made. The endoscope will then be passed through the pharynx and larynx and into the trachea. The endotracheal tube, which will have been mounted on the fibrescope, will then be advanced over the fibrescope which will guide it into the trachea. Thermosoftened, lubricated tubes, size 7mm or 6.5 mm, for males or females respectively, will be used. The ease of navigability of the tube through the nose (easy, mild resistance, moderate resistance or obstructed - not used) will be noted. If undue resistance to tube advancement is encountered in a nostril that has been selected randomly, the tube and fibrescope will be removed and the other nostril will be used. If undue resistance is still encountered, orotracheal intubation will be performed with a Macintosh laryngoscope and the options for further management of the patient will be discussed with the surgeon. If undue resistance is encountered in a nostril that has been selected as the most patent, the tube and fibrescope will be removed and orotracheal intubation will be performed with a Macintosh laryngoscope. The options for further management will then be discussed with the surgeon. (The inability to intubate both nostrils in a patient with an otherwise normal airway is a recognised problem, but in clinical practice it is a very rare event. It may occur perhaps once in approximately 500-1000 patients. The sequence of events described reflects normal clinical practice and is given in detail for completeness. In the great majority of such cases, the best option available is for the surgeon to perform the patients surgery with the orotracheal tube in study.

Five minutes after successful nasal intubation the severity of the epistaxis will be estimated by a blinded observer (AM or IS) by means of pharyngeal inspection and aspiration of the pharynx using a 1 2F suction catheter with a length of 45cm, attached to suction tubing with an internal diameter of 7mm and a length of 2.5 metre. Epistaxis will be defined as:

1. No epistaxis
2. Mild epistaxis - blood on tube or staining of posterior pharyngeal wall only
3. Moderate epistaxis - blood pooling in the pharynx of sufficient quantity to be aspirated into the suction catheter but not into the suction tubing.
4. Severe - blood pooling in the pharynx, of sufficient quantity to be aspirated into the suction tubing. The patients surgical treatment will then proceed as normal.

The videotape recordings will be analysed later by an otolaryngologist (CJ) who will confirm or refute the anaesthetic diagnoses. Will be unaware of the details and the results of the nasal intubations. Nasal abnormalities will be identified and classified as septal deviations (minor, major or impactions), septal spurs, hypertrophied turbinates, polyps, etc. According to the presence or absence of intranasal abnormalities, the nose will be classified as one nostril more patent than the other (left or right nostril best) or nostrils equally patent. In the Macintosh group, a random, selection of nostril to be intubated will be made. The same type of endotracheal tube (Thermosoftened, lubricated, size 7mm or 6.5mm for males or females respectively) will be advanced through the nose and into the pharynx, where it will be identified by a Macintosh laryngoscope inserted through the mouth. The tube will then be advanced through the larynx into the trachea, with the aid of Magills forceps if necessary. The ease of navigability of the tube through the nose will be assessed as above. If undue resistance to tube advancement is encountered the tube will be removed and the other nostril~ will be used. If undue resistance is still encountered, orotracheal intubation will be performed with a Macintosh laryngoscope and the options for further management will be discussed with the surgeon.

Five minutes after successful nasal intubation, epistaxis will be estimated by a blind observer, as above. The patients surgical treatment will then proceed as normal.

The null hypothesis is that there is no difference in the incidence of epistaxis between the two groups, The alternative hypothesis is that there is a difference in the incidence of epistaxis between the two groups; that the endoscopic selection of nostril to be intubated followed by fibreoptic intubation has had an effect on the incidence of epistaxis. In order to assess the effect of fibreoptic intubation, it is essential to have a concurrent comparison, a control group, who receive a standard technique. Without a control group, it is impossible to make an objective evaluation of the effectiveness of the intervention. It is essential to avoid researcher bias in this type of investigation. Therefore, the observer responsible for assessing the degree of epistaxis will be blinded and unaware of which type of intubation has been performed. Participants will be exposed to no increased risk and very little inconvenience. Their tracheas will be intubated by one of the established, accepted, standard methods of nasotracheal intubation - the Macintosh or the fibreoptic technique. It is normal practice for the axillofacial surgeon to first aspirate the pharynx to remove any blood before inserting the throat pack, to prevent contamination of the airway. The surgical and nursing staff involved have been consulted during the design of the investigation and have given their support.

Patients will be invited to consider participating in the study in the pre-clerking clinic approximately one week before surgery. The broad timetable for the study is as follows:

Preparation time - 3 months

Collecting data - 12 to 18 months

Interpreting and analysing findings - 3 months

Final report - at 2 years

Intervention Type

Procedure/Surgery

Phase

Not Specified

Primary outcome(s)

Incidence and severity of epistaxis

Key secondary outcome(s)

Not provided at time of registration

Completion date

04/01/2008

Eligibility

Key inclusion criteria

1. The patients involved will be scheduled for elective surgery on Maxillofacial operating lists. Potential participants will be identified when they attend the surgical pro-clerking clinic, approximately one week before the planned surgery. Suitable patients will be those in whom nasotracheal intubation is essential, ASA classification 1 or 2, with no significant undercurrent illness.
2. A clinical history will be taken and medical examination performed on potential participants. If inclusion criteria are present and exclusion criteria are absent, three questions will be asked:
 - 2.1 Do you have any difficulty breathing through your nose?
 - 2.2 Can you usually breathe clearly through both nostrils?

- 2.3 Can you usually breathe equally through both nostrils or is one nostril clearer than the other?
3. Asymptomatic patients who report being able to breathe clearly and equally through both nostrils will be invited to consider participating in the clinical investigation. A full explanation will be given and questions answered. The patient will be given a copy of the patient information sheet. S/he will then be allowed to think about the proposal and will then be seen again on the day of operation.
4. Patients in whom nasotracheal intubation is an essential part of their anaesthetic management. It is not ethical to perform a potentially traumatic nasotracheal intubation unless it is required to facilitate the planned surgery.
5. ASA physical status 1 or 2. Only patients who present no increased anaesthetic risks will be studied
6. Aged 16 and over undergoing elective surgery
7. Asymptomatic patients who report being able to breathe clearly and equally through both nostrils (if one nostril is reported to be clearer, then randomisation of nostril for intubation must not be performed)
8. Able and willing to give informed written consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

1. Morbid obesity - BMI>35 (anaesthetic risk associated with intubation)
2. Oesophageal reflux (anaesthetic risk associated with intubation)
3. Difficult tracheal intubation (anaesthetic risk associated with intubation)
4. History of nasal trauma (probable distorted nasal architecture)
5. History of nasal obstruction or nasal pathology (should have fiberoptic nasendoscopy to assess nasal cavities)
6. Bleeding diathesis or taking anticoagulant drugs (nasal intubation contra-indicated because of risk of haemorrhage)

Date of first enrolment

04/01/2006

Date of final enrolment

04/01/2008

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Selly Oak Hospital
Birmingham
United Kingdom
B29 6JD

Sponsor information

Organisation

Record Provided by the NHSTCT Register - 2007 Update - Department of Health

Funder(s)

Funder type

Government

Funder Name

University Hospital Birmingham NHS Trust (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration